Navigation Links
OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
Date:6/21/2010

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceuticals have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, OGX-011/TV-1011. OGX-011/TV-1011 is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of OGX-011/TV-1011 in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011; OGX-427 is in Phase 1 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011/TV-1011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to target and inhibit production of specific proteins which OncoGenex believes are important in tumor progression and treatment resistance. OncoGenex and Isis partnered in the successful discovery of OGX-011/TV-1011, OGX-427 and OGX-225 and with respect to OGX-011/TV-1011, in its initial development. In 2008, OncoGenex and Isis amended their OGX-011/TV-1011 agreement to provide OncoGenex with sole rights to OGX-011/TV-1011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011/TV-1011, OGX-427 and OGX-225 was discovered by the Uni
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Calabasas, CA (PRWEB) July 10, 2014 ... academic institutions and professional associations, addressed the challenges of ... & Medical Device Industries” through strategic sourcing. Describing the ... ) with the Supply Chain Management Institute ( SCMI) ... the event on June 24 at the Kroc Institute ...
(Date:7/10/2014)... , July 10, 2014 Research ... addition of the "International Photonic Integrated Circuit ... Forecasts to 2019" report to their offering. ... The concept of photonic integration traces its ... century. The promise of photonic integration went unexplored ...
(Date:7/10/2014)... study published today in the journal PNAS (Proceedings ... that time of day and sleep deprivation have a ... crucial when looking at the best time of day ... disease, and for administering medicines effectively. , Researchers from ... Research, London, investigated the links between sleep deprivation, body ...
(Date:7/10/2014)... out for crude 3-D glasses, polarized glasses, and ... basic devices, used to trick the brain into ... rendered obsolete with the introduction of new holography ... TAU doctoral students Yuval Yifat, Michal Eitan, and ... on nanoantennas that could be used for security ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Time of day crucial to accurately test for diseases, new research finds 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... would let you see a virus in a drop of blood ... says Durdu Guney, make ultra-high-resolution microscopes as commonplace as cameras in ... also known as a perfect lens, though people are trying. Optical ... limit, so even the best won,t usually let us see objects ...
... of electronics at the nanoscale may be even ... conductance in ferroelectric nanodomains by researchers at Oak ... their polarization with the application of an electric ... as ultrasound machines and sensors. Now, discoveries about ...
... 2012 Advanstar|CBI recently announced the full agenda for ... Forum takes place March 6-7, 2012 in Baltimore, MD. ... Eli Lilly, Genentech, AstraZeneca, Shire Human Genetic Therapies and ... Needy Meds recently interviewed PAP,s Senior Program Manager, Sharon ...
Cached Biology Technology:Almost perfect: A breakthrough in superlens development 2ORNL experiments prove nanoscale metallic conductivity in ferroelectrics 2
(Date:7/11/2014)... BostonThe American Society for Bone and Mineral Research awarded ... of Medicine (BUSM), with the 2014 Louis V. Avioli ... at BUSM, is internationally known for revolutionizing the understanding ... , The award honors a member of the ... fundamental contributions to bone and mineral basic research. It ...
(Date:7/11/2014)... of Standards and Technology (NIST) need a special ... often prove that necessity is truly the mother ... M. Lorna De Leoz and Stephen Stein, NIST ... Glycomics is the study of the abundant, often-branched ... proteins and lipids and influence cellular processes, including ...
(Date:7/11/2014)... of researchers, including scientists from the Max Planck Institute ... a major step in understanding photosynthesis, the process by ... oxygen in its atmosphere and which is therefore crucial ... , The researchers report the first direct visualization of ... step in which a specific protein complex, photosystem II, ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2A first direct glimpse of photosynthesis in action 2
... Chinese . College Park, MD (August 3, 2010) ... in molecular biology today. The devices, which can be used ... sequences, are employed in everything from forensic analysis to disease ... colleagues at Simon Fraser University in Burnaby, Canada have combined ...
... YORK, N.Y., August 3, 2010) Autism Speaks, ... importance of research on environmental risk factors for ... on Environment & Public Works, Subcommittee on Children,s ... health factors associated with autism spectrum disorders (ASD) ...
... of dollars to cap it, and it could take billions ... Gulf of Mexico is acknowledged the environmental catastrophe of the ... help "bioremediate" the remaining problems. Prof. Eugene Rosenberg ... Molecular Microbiology and Biotechnology are using naturally occurring oil-munching bacteria, ...
Cached Biology News:Autism Speaks on US Senate hearing on potential environmental health factors in autism 2Autism Speaks on US Senate hearing on potential environmental health factors in autism 3A nemesis for oil spills 2
... MagicMark XP Western Protein Standards are ... protein molecular weight estimation directly on ... an IgG binding site, allowing direct ... used to detect your target protein ...
... TOPO Cloning is ... available for cloning PCR ... and Zero Blunt TOPO ... and activated with topoisomerase ...
... Conjugated peptides or recombinant proteins ... to produce antibodies in 2 rabbits. pre-immune ... ELISA test until the titer reaches 1:4,000 ... Protein G purification Antibodies are eluted ...
... Immunogen: Recombinant human IDO ... for the ~44 kDa human ... (positive control: IFN-Gamma-stimmulated Human peripheral ... homology reactivity with mouse and ...
Biology Products: